Immune thrombocytopenia (ITP) is the most common platelet disorder in children, peaking between the ages of 1-7.The first line therapy consists of intravenous immunoglobulin, anti-D immunoglobulin or corticosteroids. Second-line treatment options are immunosuppressive therapy, Rituximab.Thrombopoietin receptor agonists are used, which increase platelet production in the bone marrow. Our case report on a child with refractory chronic ITP, who failed the first and second line therapy.
Journal Information
Vol. 43. Issue S3.
Pages S56-S57 (November 2021)
Vol. 43. Issue S3.
Pages S56-S57 (November 2021)
PP 62
Open Access
THE USE OF ROMIPLOSTIM IN AN INFANT
Visits
1138
Fatma Burçin KURTİPEK, Turan BAYHAN, Vildan ÇULHA, Neşe YARALI
Ankara City Hospital
This item has received
Article information
Special issue
Case report
Full text is only aviable in PDF